Research programme: cancer therapeutics - Ability Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Ability Pharmaceuticals

Alternative Names: ABTL 0814; ABTL 0815; ABTL 1014; ABTL 1216; LP20104

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals
  • Class
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies

Most Recent Events

  • 05 Jan 2017 Preclinical development is ongoing for haematological malignancies and cancer in Spain (Ability Pharmaceuticals pipeline, January 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top